| Literature DB >> 32282879 |
Antoine Chaillon1, Adriane Wynn2, Tatyana Kushner3, Nancy Reau4, Natasha K Martin1,5.
Abstract
To inform proposed changes in U.S. HCV screening guidelines, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and should be recommended nationally.Entities:
Keywords: antenatal; economic; hepatitis c virus; pregnancy; testing; treatment
Year: 2020 PMID： 32282879 DOI： 10.1093/cid/ciaa362
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079